Recombinant human thyroid-stimulating hormone: Pharmacology, clinical applications and potential uses

BioDrugs

Volumn 17, Issue 1, 2003, Pages 19-38

  Emerson, Charles H ^a   Torres, Mira S T ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHORIONIC GONADOTROPIN; FOLLITROPIN; IODINE 131; IODOTHYRONINE; LIOTHYRONINE; LUTEINIZING HORMONE; PROTIRELIN; RADIOACTIVE IODINE; RECOMBINANT THYROTROPIN; THYROTROPIN; THYROTROPIN RECEPTOR; THYROXINE;

ASTHENIA; CLINICAL TRIAL; DIFFERENTIAL DIAGNOSIS; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; GOITER; HEADACHE; HORMONE SYNTHESIS; HUMAN; HYPOTHYROIDISM; NAUSEA; NONHUMAN; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION; THYROID CANCER; THYROID FUNCTION; THYROID SCINTISCANNING; THYROIDECTOMY; THYROTOXICOSIS;

CLINICAL TRIALS; GOITER, NODULAR; HUMANS; HYPOTHYROIDISM; IODINE RADIOISOTOPES; NEOPLASM, RESIDUAL; PROTEIN ISOFORMS; PROTEIN SUBUNITS; RECOMBINANT PROTEINS; THYROID NEOPLASMS; THYROIDECTOMY; THYROTOXICOSIS; THYROTROPIN;

EID: 0037277921     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200317010-00003     Document Type: Review

References (163)

1. Will RG. An overview of Creutzfeldt-Jakob disease associated with the use of human pituitary growth hormone. Dev Biol Stand 1991; 75: 85-6
2. Bannister BA, McCormick A. Creutzfeldt-Jakob disease with reference to the safety of pituitary growth hormone. J Infect 1987; 14: 7-12
3. Kirkpatrick CH, Meek JC, Rich RR. Mechanism of allergy to components of commercial bovine thyrotropin. J Allergy Clin Immunol 1973; 51: 296-302
4. Krishnamurthy GT. Human reaction to bovine TSH: concise communication. J Nucl Med 1978; 19: 284-6
5. Sain A, Sham R, Singh A, et al. Erroneous thyroid-stimulating hormone radio-immunoassay results due to interfering antibovine thyroid-stimulating hormone antibodies. Am J Clin Pathol 1979; 71: 540-2
6. Sherman WB, Werner SC. Generalized allergic reaction to bovine thyrotropin. JAMA 1964; 190: 244-5
7. Weintraub BD, Szkudlinski MW. Development and in vitro characterization of human recombinant thyrotropin. Thyroid 1999; 9: 447-50
8. Meier C. Braverman L, Ebner S, et al. Diagnostic use of recombinant human thyrotropin in patients with thyroid carcinoma (phase I/II study). J Clin Endocrinol Metab 1994; 78: 188-96
9. Ladenson PW, Braverman LE, Mazzaferri EL, et al. Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma [see comments]. N Engl J Med 1997; 337: 888-96
10. Haugen BR, Pacini F, Reiners C, et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab 1999; 84: 3877-85
11. Park ES, Kim H, Sub JM, et al. Involvement of JAK/STAT (Janus kinase/signal transducer and activator of transcription) in the thyrotropin signaling pathway. Mol Endocrinol 2000; 14: 662-70
12. Robbins J. Pharmacology of bovine and human thyrotropin: an historical perspective. Thyroid 1999; 9: 451-3
13. Magnet JA. Thyroid-stimulating hormone: biosynthesis, cell biology, and bioactivity. Endocr Rev 1990; 11: 354-85
14. Di Cerbo A, Corda D. Signaling pathways involved in thyroid hyperfunction and growth in Graves' disease. Biochimie 1999; 81: 415-24
15. Roger PP, Christophe D, Dumont JE, et al. The dog thyroid primary culture system: a model of the regulation of function, growth and differentiation expression by cAMP and other well-defined signaling cascades. Eur J Endocrinol 1997; 137: 579-98
16. Gesundheit N, Petrick PA, Nissim M, et al. Thyrotropin-secreting pituitary adenomas: clinical and biochemical heterogeneity. Case reports and follow-up of nine patients. Ann Intern Med 1989: 111: 827-35
17. Vassart G, Dumont JE. The thyrotropin receptor and the regulation of thyrocyte function and growth. Endocr Rev 1992; 13: 596-611
18. Rapoport B, Chazenbalk GD, Jaume JC, et al. The thyrotropin (TSH) receptor: interaction with TSH and autoantibodies. Endocr Rev 1998; 19: 673-716
19. Sanders J, Oda Y, Roberts SA, et al. Understanding the thyrotropin receptor function-structure relationship. Baillieres Clin Endocrinol Metab 1997; 11: 451-79
20. Misrahi M, Loosfelt H, Atger M, et al. Cloning, sequencing and expression of human TSH receptor. Biochem Biophys Res Commun 1990; 166: 394-403
21. Loosfelt H, Pichon C, Jolivet A, et al. Two-subunit structure of the human thyrotropin receptor. Proc Natl Acad Sci U S A 1992; 89: 3765-9
22. Hara T, Namba H, Takamura N, et al. Thyrotropin regulates c-Jun N-terminal kinase (JNK) activity through two distinct signal pathways in human thyroid cells. Endocrinology 1999; 140: 1724-30
23. Dumont JE. The action of thyrotropin on thyroid metabolism. Vitam Horm 1971; 29: 287-412
24. Laurent E, Mockel J, Van Sande J, et al. Dual activation by thyrotropin of the phospholipase C and cyclic AMP cascades in human thyroid. Mol Cell Endocrinol 1987; 52: 273-8
25. Raspe E, Laurent E, Andry G, et al. ATP, bradykinin, TRH and TSH activate the Ca(2+)-phosphatidylinositol cascade of human thyrocytes in primary culture. Mol Cell Endocrinol 1991; 81: 175-83
26. Corvilain B, Laurent E, Lecomte M, et al. Role of the cyclic adenosine 3′,5′-monophosphate and the phosphatidylinositoI-Ca2+ cascades in mediating the effects of thyrotropin and iodide on hormone synthesis and secretion in human thyroid slices. J Clin Endocrinol Metab 1994; 79: 152-9
27. Spitzweg C, Heufelder AE, Morris JC. Thyroid iodine transport. Thyroid 2000 Apr; 10: 321-30
28. Yoshidi A, Taniguchi S, Hisatome I, et al. Pendrin is an iodide-specific apical porter responsible for iodide efflux from thyroid cells. J Clin Endocrinol Metab 2002; 87: 3356-61
29. Ohtaki S, Nakagawa H, Nakamura M, et al. Thyroid peroxidase: experimental and clinical integration. Endocr J 1996; 43: 1-14
30. Taurog A. Molecular evolution of thyroid peroxidase. Biochimie 1999; 81: 557-62
31. Dunn JT, Dunn AD. The importance of thyroglobulin structure for thyroid hormone biosynthesis. Biochimie 1999; 81: 505-9
32. Baudry N, Lejeune PJ, Niccoli P, et al. Dityrosine bridge formation and thyroid hormone synthesis are tightly linked and are both dependent on N-glycans. FEBS Lett 1996; 396: 223-6
33. Bernier-Valentin F, Kostrouch Z, Rabilloud R, et al. Coated vesicles from thyroid cells carry iodinated thyroglobulin molecules. First indication for an internalization of the thyroid prohormone via a mechanism of receptor-mediated endocytosis. J Biol Chem 1990; 265: 17373-80
34. Kostrouch Z, Munari-Silem Y, Rajas F, et al. Thyroglobulin internalized by thyrocytes passes through early and late endosomes. Endocrinology 1991; 129: 2202-11
35. Bernier-Valentin F, Kostrouch Z, Rabilloud R, et al. Analysis of the thyroglobulin internalization process using in vitro reconstituted thyroid follicles: evidence for a coated vesicle-dependent endocytic pathway. Endocrinology 1991; 129: 2194-201
36. Dunn AD, Crutchfield HE, Dunn JT. Proteolytic processing of thyroglobulin by extracts of thyroid lysosomes. Endocrinology 1991; 128: 3073-80
37. Rousset B, Selmi S, Alquier C, et al. In vitro studies of the thyroglobulin degradation pathway: endocytosis and delivery of thyroglobulin to lysosomes, release of thyroglobulin cleavage products -iodotyrosines and iodothyronines, Biochimie 1989; 71: 247-62
38. Rousset B, Selmi S, Bornet H, et al. Thyroid hormone residues are released from thyroglobulin with only limited alteration of the thyroglobulin structure. J Biol Chem 1989; 264: 12620-6
39. Uller RP, Van Herle AJ, Chopra IJ. Comparison of alterations in circulating thyroglobulin, triiodothyronine and thyroxine in response to exogenous (bovine) and endogenous (human) thyrotropin. J Clin Endocrinol Metab 1973; 37: 741-5
40. Uller R, van Herle A, Chopra I. Thyroidal response to graded doses of bovine thyrotropin. J Clin Endocrinol Metab 1977; 45: 312-8
41. Unger J. van Heuverswyn B, Decoster C, et al. Thyroglobulin and thyroid hormone release after intravenous administration of bovine thyrotropin in man. J Clin Endocrinol Metab 1980; 51: 590-4
42. Ramirez L, Braverman L, White B, et al. Recombinant human thyrotropin is a potent stimulator of thyroid function in normal subjects. J Clin Endocrinol Metab 1997; 82: 2836-9
43. Torres MS, Ramirez L, Simkin PH, et al. Effect of various doses of recombinant human thyrotropin on the thyroid radioactive iodine uptake and serum levels of thyroid hormones and thyroglobulin in normal subjects. J Clin Endocrinol Metab 2001; 86: 1660-4
44. Colletta G, Cirafici AM. TSH is able to induce cell cycle-related gene expression in rat thyroid cell. Biochem Biophys Res Commun 1992; 183: 265-72
45. Filetti S, Damante G, Foti D. Thyrotropin stimulates glucose transport in cultured rat thyroid cells. Endocrinology 1987; 120: 2576-81
46. Haraguchi K, Rani CS, Field JB. Effects of thyrotropin, carbachol, and protein kinase-C stimulators on glucose transport and glucose oxidation by primary cultures of dog thyroid cells. Endocrinology 1988; 123: 1288-95
47. Grossmann M, Weintraub BD, Szkudlinski MW. Novel insights into the molecular mechanisms of human thyrotropin action: structural, physiological, and therapeutic implications for the glycoprotein hormone family. Endocr Rev 1997; 18: 476-501
48. Fiddes JC, Goodman HM. The gene encoding the common alpha subunit of the four human glycoprotein hormones. J Mol Appl Genet 1981; 1: 3-18
49. Lustbader JW. Lobel L. Wu H. et al. Structural and molecular studies of human chorionic gonadotropin and its receptor. Recent Prog Horm Res 1998; 53: 395-424
50. Pigny P, Berault A, Dewailly D, et al. Glycoprotein hormones, glycosylation and biological activity. Ann Biol Clin (Paris) 1992; 50: 557-64
51. Taylor T, Weintraub BD. Altered thyrotropin (TSH) carbohydrate structures in hypothalamic hypothyroidism created by paraventricular nuclear lesions are corrected by in vivo TSH-releasing hormone administration. Endocrinology 1989; 125: 2198-203
52. Taylor T, Gesundheit N, Gyves PW, et al. Hypothalamic hypothyroidism caused by lesions in rat paraventricular nuclei alters the carbohydrate structure of secreted thyrotropin. Endocrinology 1988: 122: 283-90
53. Beck-Peccoz P, Persani L. Variable biological activity of thyroid-stimulating hormone. Eur J Endocrinol 1994; 131: 331-40
54. Persani L. Hypothalamic thyrotropin-releasing hormone and thyrotropin biological activity. Thyroid 1998; 8: 941-6
55. Weintraub BD, Wondisford FE, Farr EA, et al. Pre-translational and post-translational regulation of TSH: relationship to bioactivity. Horm Metab Res Suppl 1990; 23: 9-11
56. Schaaf L, Leiprecht A, Saji M, et al. Glycosylation variants of human TSH selectively activate signal transduction pathways. Mol Cell Endocrinol 1997; 132: 185-94
57. Thotakura NR, Desai RK, Bates LG, et al. Biological activity and metabolic clearance of a recombinant human thyrotropin produced in Chinese hamster ovary cells. Endocrinology 1991; 128: 341-8
58. Szkudlinski MW, Thotakura NR, Bucci I, et al. Purification and characterization of recombinant human thyrotropin (TSH) isoforms produced by Chinese hamster ovary cells: the role of sialylation and sulfation in TSH bioactivity. Endocrinology 1993; 133: 1490-503
59. Grossmann M, Szkudlinski MW, Tropea JE, et al. Expression of human thyrotropin in cell lines with different glycosylation patterns combined with mutagenesis of specific glycosylation sites. Characterization of a novel role for the oligosaccharides in the in vitro and in vivo bioactivity. J Biol Chem 1995; 270: 29378-85
60. Szkudlinski MW, Thotakura NR, Weintraub BD. Subunit-specific functions of N-linked oligosaccharides in human thyrotropin: role of terminal residues of alpha- and beta-subunit oligosaccharides in metabolic clearance and bioactivity. Proc Natl Acad Sci U S A 1995; 92: 9062-6
61. Grossmann M, Wong R. Teh NG, et al. Expression of biologically active human thyrotropin (hTSH) in a baculovirus system: effect of insect cell glycosylation on hTSH activity in vitro and in vivo. Endocrinology 1997; 138: 92-100
62. Szkudlinski MW, Grossmann M, Leitolf H, et al. Human thyroid-stimulating hormone: structure-function analysis. Methods 2000 May; 21: 67-81
63. Persani L. Terzolo M, Asteria C, et al. Circadian variations of thyrotropin bioactivity in normal subjects and patients with primary hypothyroidism. J Clin Endocrinol Metab 1995; 80: 2722-8
64. Papandreou MJ, Persani L, Asteria C, et al. Variable carbohydrate structures of circulating thyrotropin as studied by lectin affinity chromatography in different clinical conditions. J Clin Endocrinol Metab 1993; 77: 393-8
65. Dahlberg PA, Petrick PA, Nissim M, et al. Intrinsic bioactivity of thyrotropin in human serum is inversely correlated with thyroid hormone concentrations. Application of a new bioassay using the FRTL-5 rat thyroid cell strain. J Clin Invest 1987; 79: 1388-94
66. Nissim M, Lee KO, Petrick PA, et al. A sensitive thyrotropin (TSH) bioassay based on iodide uptake in rat FRTL-5 thyroid cells: comparison with the adenosine 3′,5′-monophosphate response to human serum TSH and enzymatically deglycosylated bovine and human TSH. Endocrinology 1987; 121: 1278-87
67. Persani L, Tonacchera M, Beck-Peccoz P, et al. Measurement of cAMP accumulation in Chinese hamster ovary cells transfected with the recombinant human TSH receptor (CHO-R): a new bioassay for human thyrotropin. J Endocrinol Invest 1993; 16: 511-9
68. Beck-Peccoz P, Amr S, Menezes-Ferreira MM, et al. Decreased receptor binding of biologically inactive thyrotropin in central hypothyroidism. Effect of treatment with thyrotropin-releasing hormone. N Engl J Med 1985; 312: 1085-90
69. Horimoto M, Nishikawa M, Yoshikawa N, et al. A sensitive and practical bioassay for thyrotropin (TSH): comparison of the bioactivity of TSH in normal subjects and in patients with primary hypothyroidism. Endocrinol Jpn 1990; 37: 577-81
70. Persani L, Asteria C, Tonacchcra M, et al. Evidence for the secretion of thyrotropin with enhanced bioactivity in syndromes of thyroid hormone resistance. J Clin Endocrinol Metab 1994; 78: 1034-9
71. Beck-Peccoz P, Piscitelli G, Amr S. et al. Endocrine, biochemical, and morphological studies of a pituitary adenoma secreting growth hormone, thyrotropin (TSH), and alpha-subunit: evidence for secretion of TSH with increased hioacdvity. J Clin Endocrinol Metab 1986; 62: 704-11
72. Shupnik MA, Greenspan SL, Ridgway EC. Transcriptional regulation of thyrotropin subunit genes by thyrotropin-releasing hormone and dopamine in pituitary cell culture. J Biol Chem 1986; 261: 12675-9
73. Gesundheit N, Magner JA, Chen T, et al. Differential sulfation and sialylation of secreted mouse thyrotropin (TSH) subunits: regulation by TSH-releasing hormone. Endocrinology 1986; 119: 455-63
74. Gesundheit N, Fink DL, Silverman LA. et al. Effect of thyrotropin-releasing hormone on the carbohydrate structure of secreted mouse thyrotropin. Analysis by lectin affinity chromatography. J Biol Chem 1987; 262: 5197-203
75. Ronin C, Stannard BS, Weintrauh BD. Differential processing and regulation of thyroid-stimulating hormone subunit carbohydrate chains in thyrotropic tumors and in normal and hypothyroid pituitaries. Biochemistry 1985; 24: 5626-31
76. Menezes-Ferreira MM, Petrick PA, Weintraub BD. Regulation of thyrotropin (TSH) bioactivity by TSH-releasing hormone and thyroid hormone. Endocrinology 1986; 118: 2125-30
77. Yamada M, Saga Y, Shibusawa N, et al. Tertiary hypothyroidism and hyperglycemia in mice with targeted disruption of the thyrotropin-releasing hormone gene. Proc Natl Acad Sci U S A 1997; 94; 10862-7
78. Abel ED, Kaulbach HC, Campos-Barros A, et al. Novel insight from transgenic mice into thyroid hormone resistance and the regulation of thyrotropin. J Clin Invest 1999; 103: 271-9
79. Snyder PJ, Utiger RD. Inhibition of thyrotropin response to thyrotropin-releasing hormone by small quantities of thyroid hormones. J Clin Invest 1972; 51: 2077-84
80. Segerson TP, Kauer J, Wolfe HC, et al. Thyroid hormone regulates TRH biosynthesis in the paraventricular nucleus of the rat hypothalamus. Science 1987; 238: 78-80
81. Koller KJ, Wolff RS, Warden MK, et al. Thyroid hormones regulate levels of thyrotropin-releasing-hormone mRNA in the paraventricular nucleus. Proc Natl Acad Sci U S A 1987; 84: 7329-33
82. Kakucska I, Rand W, Lechan RM. Thyrotropin-releasing hormone gene expression in the hypothalamic paraventricular nucleus is dependent upon feedback regulation by both triiodothyronine and thyroxine. Endocrinology 1992; 130: 2845-50
83. Faglia G, Bitensky L, Pinchera A, et al. Thyrotropin secretion in patients with central hypothyroidism: evidence for reduced biological activity of immunoreactive thyrotropin. J Clin Endocrinol Metab 1979; 48: 989-98
84. Emerson CH. Central hypothyroidism and hyperthyroidism. Med Clin North Ann 1985; 69: 1019-34
85. Miura Y, Perkel VS, Papenberg KA, et al. Concanavalin-A, lentil, and ricin lectin affinity binding characteristics of human thyrotropin: differences in the sialylation of thyrotropin in sera of euthyroid, primary, and central hypothyroid patients. J Clin Endocrinol Metab 1989; 69: 985-95
86. DeCherney GS, Gesundheit N, Gyves PW, et al. Alterations in the sialylation and sulfation of secreted mouse thyrotropin in primary hypothyroidism. Biochem Biophys Res Commun 1989; 159: 755-62
87. Schaaf L, Trojan J, Helton TE, et al. Serum thyrotropin (TSH) heterogeneity in euthyroid subjects and patients with subclinical hypothyroidism: the core fucose content of TSH-releasing hormone-released TSH is altered, but not the net charge of TSH. J Endocrinol 1995; 144: 561-71
88. Wondisford FE, Radovick S, Moates JM, et al. Isolation and characterization of the human thyrotropin beta-subunit gene. Differences in gene structure and promoter function from murine species. J Biol Chem 1988; 263: 12538-42
89. Watanabe S, Hayashizaki Y, Endo Y, et al. Production of human thyroid-stimulating hormone in Chinese hamster ovary cells. Biochem Biophys Res Commun 1987; 149: 1149-55
90. Cole ES, Lee K, Lauziere K, et al. Recombinant human thyroid stimulating hormone: development of a biotechnology product for detection of metastatic lesions of thyroid carcinoma. Biotechnology 1993; 11: 1014-24
91. Hussain A, Zimmerman CA, Boose JA, et al. Large scale synthesis of recombinant human thyrotropin using methotrexate amplification: chromatographic, immunological, and biological characterization. J Clin Endocrinol Metab 1996; 81: 1184-8
92. Rafferty B, Gaines Dos R. Comparison of pituitary and recombinant human thyroid-stimulating hormone (rhTSH) in a multicenter collaborative study: establishment of the first World Health Organization reference reagent for rhTSH. Clin Chem 1999; 45: 2207-15
93. Szkudlinski MW, Thotakura NR, Tropea JE, et al. Asparagine-linked oligosaccharide structures determine clearance and organ distribution of pituitary and recombinant thyrotropin. Endocrinology 1995; 136: 3325-30
94. Huber GK, Fong P, Concepcion ES, et al. Recombinant human thyroid-stimulating hormone: initial bioactivity assessment using human fetal thyroid cells. J Clin Endocrinol Metab 1991; 72: 1328-31
95. Braverman L, Pratt B, Ebner S, et al. Recombinant human thyrotropin stimulates thyroid function and radioactive iodine uptake in the rhesus monkey. J Clin Endocrinol Metab 1992; 74: 1135-9
96. Huysmans DA, Nieuwlaat WA, Erdtsieck RJ, et al. Administration of a single low dose of recombinant human thyrotropin significantly enhances thyroid radioiodide uptake in nontoxic nodular goiter. J Clin Endocrinol Metab 2000; 85: 3592-6
97. East-Palmer J, Szkudlinski MW, Lee J. et al. A novel, nonradioactive in vivo bioassay of thyrotropin (TSH). Thyroid 1995; 5: 55-9
98. Colzani RM, Alex S, Fang SL, et al. The effect of recombinant human thyrotropin (rhTSH) on thyroid function in mice and rats. Thyroid 1998; 8: 797-801
99. Thyrogen. In: Physicians Desk Reference, 56th ed. Montvale (NJ): Medical Economics Co. Inc., 2002: 1441-2
100. Ridgway EC, Weintraub BD, Maloof F, Metabolic clearance and production rates of human thyrotropin. J Clin Invest 1974; 53: 895-903
101. Kuku SF, Harsoulis P, Kjeld M, et al. Human thyrotrophic hormone kinetics and effects in euthyroid males. Horm Metab Res 1975; 7: 54-9
102. Dulgeroff AJ, Hershman JM. Medical therapy for differentiated thyroid carcinoma. Endocr Rev 1994; 15: 500-15
103. Mazzaferri EL. An overview of the management of papillary and follicular thyroid carcinoma. Thyroid 1999; 9: 421-7
104. Robbins RJ, Chon JT, Fleisher M, et al. Is the serum thyroglobulin response to recombinant human thyrotropin sufficient, by itself, to monitor for residual thyroid carcinoma? J Clin Endocrinol Metab 2002; 87: 3242-7
105. Emerson CH, Colzani R, Braverman LE. Epithelial cell thyroid cancer and thyroid stimulating hormone -when less is more. J Clin Endocrinol Metab 1997; 82: 9-10
106. Durski JM, Weigel RJ, McDougall IR. Recombinant human thyrotropin (rhTSH) in the management of differentiated thyroid cancer. Nucl Med Commun 2000; 21: 521-8
107. Hershman JM. Recombinant human thyrotropin. Thyroid 1999; 9: 419-20
108. Incerti C. Recombinant human thyroid-stimulating hormone (rhTSH): clinical development. J Endocrinol Invest 1999; 22: 8-16
109. Ladenson PW. Strategies for thyrotropin use to monitor patients witb treated thyroid carcinoma. Thyroid 1999; 9: 429-33
110. Ladenson PW. Recombinant thyrotropin versus thyroid hormone withdrawal in evaluating patients with thyroid carcinoma. Semin Nucl Med 2000; 30: 98-106
111. Mariani G, Ferdeghini M, Augeri C, et al. Clinical experience with recombinant human thyrotrophin (rhTSH) in the management of patients with differentiated thyroid cancer. Cancer Biother Radiopharm 2000; 15: 211-7
112. Mazzaferri EL, Kloos RT. Using recombinant human TSH in the management of well-differentiated thyroid cancer: current strategies and future directions. Thyroid 2000 Sep; 10: 767-78
113. McDougall IR, Weigel RJ. Recombinant human thyrotropin in the management of thyroid cancer. Curr Opin Oncol 2001; 13: 39-43
114. Pacini F, Lippi F. Clinical experience with recombinant human thyroid-stimulating hormone (rhTSH): serum thyroglobulin measurement. J Endocrinol Invest 1999; 22: 25-9
115. Perros P. Recombinant human thyroid-stimulating hormone (rhTSH) in the radioabtation of well-differentiated thyroid cancer: preliminary therapeutic experience. J Endocrinol Invest 1999; 22: 30-4
116. Reiners C, Luster M, Lassmann M. Clinical experience with recombinant human thyroid-stimulating hormone (rhTSH): whole-body scanning with iodine-131. J Endocrinol Invest 1999; 22: 17-24
117. Robbins RJ, Tuttle RM, Sharaf RN, et al. Preparation by recombinant human thyrotropin or thyroid hormone withdrawal are comparable for the detection of' residual differentiated thyroid carcinoma. J Clin Endocrinol Metab 2001: 86: 619-25
118. Robbins R, Drucker W, Hann L, et al. Advances in the detection of residual thyroid carcinoma. Adv Intern Med 2001: 46: 277-94
119. Schlumberger MJ, Incerti C, Pacini F, et al. The role of recombinant thyroid-stimulating hormone (rhTSH) in the detection and management of well-differentiated thyroid carcinoma: a roundtable discussion. J Endocrinol Invest 1999; 22: 35-41
120. Schlumberger M, Ricard M, Pacini F. Clinical use of recombinant human TSH in thyroid cancer patients. Eur J Endocrinol 2000; 143: 557-63
121. Mazzaferri EL, Kloos RT. Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation? J Clin Endocrinol Metab; 87: 1490-8
122. Haugen BR, Ridgway EC, McLaughlin BA, et al. Clinical comparison of whole-body radioiodine scan and serum thyroglobulin after stimulation with recombinant human thyrotropin. Thyroid 2002; 12: 37-43
123. Giovanni V, Arianna LG, Antonio C, et al. The use of recombinant human TSH in the follow-up of differentiated thyroid cancer: experience from a large patient cohort in a single centre. Clin Endocrinol 2002; 56: 247-52
124. Berg G, Lindstedt G, Suurkula M, et al. Radioiodine ablation and therapy in differentiated thyroid cancer under stimulation with recombinant human thyroid-stimulating hormone. J Endocrinol Invest 2002; 25: 44-52
125. Wartofsky L. Management of low-risk well-differentiated thyroid cancer based only on thyroglobulin measurement after recombinant human thyrotropin. Thyroid 2002 Jul; 12 (7): 583-90
126. Pacini F, Molinaro E, Lippi F, et al. Prediction of disease status by recombinant human TSH-stimulated serum Tg in the postsurgical follow-up or differentiated thyroid carcinoma. J Clin Endocrinol Metab 2001; 86: 5686-90
127. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994; 97: 418-28
128. Petrich T, Borner AR, Otto D, et al. Influence of rhTSH on [(18)F]flurodeoxyglucose uptake by differentiated thyroid carcinoma. Eur J Nucl Med 2002; 29: 641-7
129. Vargas GE, Uy H, Bazan C, et al. Hemiplegia after thyrotropin alfa in a hypothyroid patient with thyroid carcinoma metastatic to the brain. J Clin Endocrinol Metab 1999; 84: 3867-71
130. Braga M, Ringel MD, Cooper DS. Sudden enlargement of local recurrent thyroid tumor after recombinant human TSH administration. J Clin Endocrinol Metab 2001; 86: 5148-51
131. Robbins RJ, Voelker E, Wang W, et al. Compassionate use of recombinant human thyrotropin to facilitate radioiodine therapy: case report and review of the literature. Endocr Pract 2000; 6: 460-4
132. Lippi F, Capezzone M, Angelini F, et al. Radioiodine treatment of metastatic differentiated thyroid cancer on L-thyroxine using recombinant TSH. Eur J Endocrinol 2001; 144: 5-11
133. Luster M, Lassmann M, Haenscheid H, et al. Use of recombinant human thyrotropin before radioiodine therapy in patients with advanced differentiated thyroid carcinoma. J Clin Endocrinol Metab 2000; 85: 3640-5
134. Seidlin SM, Oshry E, Yallow AA. Spontaneous and experimentally induced uptake of radioactive iodine in metastases from thyroid carcinoma: a preliminary report. J Clin Endocrinol 1948; 8: 423-32
135. Trunnell JB, Marinelli LD, Duffy BJ, et al. The treatment of metastatic thyroid cancer with radioactive iodine: a preliminary report. J Clin Endocrinol 1949; 9: 1138-52
136. Benua RS, Sonenberg M, Leeper RD, et al. An 18 year study of the use of beef thyrotropin to increase 1131 uptake in metastatic thyroid cancer. J Nucl Med 1964; 5: 796-801
137. Hershman J, Edwards C. Serum thyrotropin (TSH) levels after thyroid ablation compared with TSH levels after exogenous bovine TSH: implications for 131-1 treatment of thyroid carcinoma. J Clin Endocrinol Metab 1972; 34: 814-8
138. Ringel M, Ladenson P. Diagnostic accuracy of 1311 scanning with recombinant human thyrotropin versus thyroid hormone withdrawal in a patient with metastatic thyroid carcinoma and hypopituitarism. J Clin Endocrinol Metab 1996; 81: 1724-5
139. Masiukiewicz US, Nakchbandi IA, Stewart AF, et al. Papillary thyroid carcinoma metastatic to the pituitary gland. Thyroid 1999; 9: 1023-7
140. Colleran KM, Burge MR. Isolated thyrotropin deficiency secondary to primary empty sella in a patient with differentiated thyroid carcinoma: an indication for recombinant thyrotropin. Thyroid 1999; 9: 1249-52
141. Luster M, Reinhardt W, Korber C, et al. The use of recombinant human TSH in a patient with metastatic follicular carcinoma and insufficient endogenous TSH production. J Endocrinol Invest 2000; 23: 473-5
142. Rotman-Pikielny P, Reynolds JC, Barker WC, et al. Recombinant human thyrotropin for the diagnosis and treatment of a highly functional metastatic struma ovarii. J Clin Endocrinol Metab 2000; 85: 237-44
143. Bray GA, Melvin KE, Chopra IJ. Effect of triiodothyronine on some metabolic responses of obese patients. Am J Clin Nutr 1973; 26: 715-21
144. Potter JD. Hypothyroidism and reproductive failure. Surg Gynecol Obstet 1980; 150: 251-5
145. Bishopric GA, Garrett NH, Nicholson WM. Clinical value of the TSH test in the diagnosis of thyroid diseases. Am J Meal 1955; 18: 15-9
146. Skillem PG, Evans BR. The thyroid stimulating hormone (TSH) test. An aid to the differential diagnosis of nontoxic disease of the thyroid. Arch Intern Med 1957; 99: 266-77
147. Rosen HN, Greenspan SL, Landsberg L, et al. Distinguishing hypothyroxinemia due to euthyroid sick syndrome from pituitary insufficiency. Isr J Med Sci 1994; 30: 746-50
148. Vanderpump MP, Tunbridge WM, French JM, et al. The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey. Clin Endocrinol (Oxf) 1995; 43: 55-68
149. Burke G. The thyrotropin stimulation test. Ann Intern Med 1968; 69: 1127-39
150. Stanley MM, Astwood EB. The response of the thyroid gland in normal human subjects to the administration of thyrotropin, as shown by studies with 1131. Endocrinology 1949; 44: 49-60
151. Querido A, Stanbury JB. The response of the thyroid gland to thyrotropic hormone as an aid in the differential diagnosis of primary and secondary hypothyroidism. J Clin Endocrinol Metab 1950; 10: 1192-201
152. Perloff WH, Levy LM, Despopoulos A. The use of thyrotropic hormone (TSH) in the diagnosis of myxedema. J Clin Endocrinot 1952; 11: 1495-502
153. Einhorn J, Larsson LG. Studies on the effect of thyrotropin on human thyroid function. J Clin Endocrinol 1959; 19: 28-34
154. Taunton O, McDaniel H, Pittman J. Standardization of TSH testing. Ann Intern Med 1965; 25: 266-77
155. Nelson J, Johnson D, Odell W. Serum TSH levels and the thyroidal response to TSH stimulation in patients with thyroid disease. Ann Intern Med 1972; 76: 47-52
156. Wiener R, Utiger RD, Lew R, et al. Age, sex, and serum thyrotropin concentrations in primary hypothyroidism. Acta Endocrinol (Copenh) 1991; 124: 364-9
157. Refetoff S, Sunthornthepvarakul T, Gottschalk ME, et al. Resistance to thyrotropin and other abnormalities of the thyrotropin receptor. Recent Prog Horm Res 1996; 51: 97-120
158. Fares FA, Levi F, Reznick AZ, et al. Engineering a potential antagonist of human thyrotropin and thyroid stimulating antibody. J Biol Chem 2001; 2000; 16: 4543-8
159. Sathekge MM, Mageza RB, Muthuphei MN, et al. Evaluation of thyroid nodules with technetium-99m MIBI and technetium-99m pertechnetate. Head Neck 2001 Apr; 23: 305-10
160. Braverman LE. Iodine and the thyroid: 33 years of study. Thyroid 1994; 4:351-6
161. Knopp J, Stolc V, Tong W. Evidence for the induction of iodide transport in bovine thyroid cells treated with thyroid-stimulating hormone or dibutyryl cyclic adenosine 3′,5′-monophosphate. J Biol Chem 1970; 245: 4403-8
162. Lawrence JE, Emerson CH, Sullaway SL, et al. The effect of recombinant human TSH on the thyroid (123)1 uptake in iodide treated normal subjects. J Clin Endocrinol Metab 2001; 86: 437-40
163. Nieuwlaat WA, Hermus AR, Sivro-Prndelj F, et al. Pretreatment with recombinant human TSH changes the regional distribution of radioiodine on thyroid scintigrams of nodular goiters. J Clin Endocrinol Metab 2001; 86: 5330-6